FIGURE 136. Cognitive outcomes (SMD) at 24–26 weeks – donepezil (all dosages) vs placebo: association of standardised treatment effect with average age of population.

FIGURE 136Cognitive outcomes (SMD) at 24–26 weeks – donepezil (all dosages) vs placebo: association of standardised treatment effect with average age of population

Area of circles is proportional to weight of each study in random-effects meta-analysis; dashed line shows univariate metaregression estimate (α = −0.073; β = 0.006; p = 0.796).

From: Appendix 7, Metaregression figures

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.